A5036932689- Hematopoietic Stem Cell Transplantation
- Fungal Infections and Studies
- Antifungal resistance and susceptibility
- Neutropenia and Cancer Infections
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Retinoids in leukemia and cellular processes
- Mesenchymal stem cell research
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Mycobacterium research and diagnosis
- Lymphoma Diagnosis and Treatment
- Kruppel-like factors research
- Bone and Joint Diseases
- Cytomegalovirus and herpesvirus research
- Pneumocystis jirovecii pneumonia detection and treatment
- Infectious Diseases and Mycology
- Blood groups and transfusion
- Cancer Treatment and Pharmacology
- Oral health in cancer treatment
- Polyomavirus and related diseases
- Eosinophilic Disorders and Syndromes
- Blood disorders and treatments
National Cancer Institute
2020-2024
National Institutes of Health
2020-2024
Center for Cancer Research
2020-2023
University Hospital Centre Zagreb
2012-2021
University of Zagreb
2011
Klinička bolnica Merkur
2008-2011
Ruxolitinib (INCB018424) is the first potent, selective, oral inhibitor of JAK1 and 2 being developed for clinical use. Its major cellular systemic effects are proliferation inhibition, apoptosis induction reduction in cytokine plasma levels, all mediated by drug's inhibition JAKs' ability to phosphorylate STAT. In initial trials its use myelofibrosis, ruxolitinib exhibited durable efficacy splenomegaly alleviation constitutional symptoms. Patients also showed weight gain improvement general...
Abstract: Ruxolitinib is an orally bioavailable, selective Janus kinase (JAK) 1 and 2 inhibitor approved for the treatment of myelofibrosis (MF), a bone marrow disease in which JAK pathway dysregulated, leading to impaired hematopoiesis immune function. By inhibiting JAK1 JAK2, ruxolitinib modulates cytokine-stimulated intracellular signaling. In phase II clinical trial patients with MF, recipients exhibited durable reductions spleen size, circulating pro-inflammatory cytokines, improvements...
Abstract Chronic graft-versus-host disease (cGVHD) remains a significant problem for patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although in vivo lymphodepletion cGVHD prophylaxis has been explored the myeloablative setting, its effects reduced-intensity conditioning (RIC) are not well described. Patients (N = 83) with hematologic malignancies underwent targeted chemotherapy followed by RIC allo-HSCT using peripheral blood cells from unrelated donors. were...
AimTo investigate the ability of two standard quality life (QOL) questionnaires – The Short Form (36-item) Health Survey (SF-36) and European Organisation for Research Treatment Cancer Quality Life Questionnaire-Core 30 (EORTC QLQ C30) to evaluate QOL in patients with chronic graft-vs-host disease (cGVHD) graded according National Institutes (NIH) consensus criteria.MethodsIn this cross-sectional study, was assessed who underwent allogeneic stem cell transplantation (allo-SCT) at University...
Chronic graft-versus-host disease (cGVHD) is the leading late complication after allogeneic hematopoietic stem cell transplantation (HSCT). Many patients receive multiple lines of systemic therapy until cGVHD resolves, but about 15% remain on treatment for more than 7 years diagnosis. This study describes clinical and biological factors who present with persisting ≥7 (persistent cGVHD). Patients persistent (n = 38) those <1 year (early cGVHD) 83) were enrolled in a prospective...
Subsequent cancer (SC) is a significant cause of morbidity and mortality in long-term survivors after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Chronic graft-versus-host disease (cGVHD) treatment-related immunosuppression have been recognized as risk factors for SC. This study sought to investigate the incidence SC patients with established cGVHD, assessed separately onset basal carcinoma (BCC) squamous (SCC)-categorized into nonmelanoma skin (NMSC)-and all cancers...
Background: Thromboembolism frequently complicates treatment of acute lymphoblastic leukemia (ALL). Aims: A single‐center retrospective study was conducted with the objective assessing risk factors for thromboembolism in adult patients ALL. Methods: The included 87 consecutive (aged 19–70 years; 57 males) treated ALL; B‐cell (n = 40), T‐cell 26), Ph+ 13), byphenotypic 3) and unclassified 5) during 10‐year period. All but one received intensive treatment, including L‐asparginase (65%)...
Background: The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era anticancer therapy. Despite many reports on anti PD-1 antibody therapy for the treatment Hodgkin's lymphoma (HL), risk infection among patients receiving nivolumab is still unknown. We are first to present real-life data complications large cohort r/r HL after (nivo) Aims: Our aim was study epidemiology adult during one year salvage with nivo CIC 725. Methods: Between 2016 and 2018...